UK-based Enesi Pharma has partnered with the US Biomedical Advanced Research and Development Authority (BARDA) to create new vaccines for protection from influenza.
Under the BARDA DRIVe initiative, the pharmaceutical company will leverage its ImplaVax needle-free device and formulation technology for developing the new vaccine candidates.
Go deeper with GlobalData
ImplaVax is designed for quick delivery of solid dose vaccine implants under the skin. The technology enables vaccination with reusable needle-free device.
Enesi Pharma noted that the ImplaVax technology possesses the potential to elicit better immune responses, as well as minimise storage and distribution costs.
The combination of the ImplaVax free vaccine delivery system with an influenza vaccine is expected to improve the medication’s efficacy, thermal stability and speedy administration.
Enesi Pharma CEO David Hipkiss said: “The team at DRIVe has been incredibly supportive of Enesi and clearly recognise the need to revolutionise vaccine delivery as part of their mission to advance research and development of medical countermeasures against serious health security threats.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“This is the latest in a series of key strategic partnerships and represents the next step in our journey to make a tangible difference to global healthcare.”
The partners will carry out analytical and pre-clinical assessment of ImplaVax-powered solid dose implant variants of marketed influenza vaccines in validated models.
In addition, in vitro testing will be performed to confirm titer generation, mechanical strength and surety of implantation.
The tests will compare efficacy and dosing regimens of solid dose implants with placebo and active control delivered using needle and syringe.
These evaluations are intended to collect evidence supporting the use of this vaccination approach as a preferred method during an influenza pandemic in the future.
Earlier this month, Enesi Pharma also collaborated with the University of Oxford to develop and assess a solid dose vaccine against plague using the ImplaVax needle-free technology.
